Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

194.95 +5.64 (+2.98%)
Streaming Delayed Price Updated: 11:52 AM EDT, Jul 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9
...
82 83 Next >
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Vanguard High Dividend Yield ETF vs Vanguard Dividend Appreciation ETF: Which Is Best for You?
Vanguard has some excellent dividend ETFs, but they are right for different investors. 
Via The Motley Fool
Topics ETFs
Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with Myriad... 
Via StockStory
Topics Artificial Intelligence
Mixue Group's Splashy Debut, Kroger's Change, Stuffed Crust Pizza, and Med Spas
There's a lot going on for investors. 
Via The Motley Fool
AbbVie Options Trading: A Deep Dive into Market Sentiment
 
Via Benzinga
13 Analysts Have This To Say About AbbVie
 
Via Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
 
Via Benzinga
This Top Dividend Stock Just Entered The Weight Loss Market: Is It a Buy?
Via The Motley Fool
ReShape Lifesciences, Allarity, Exact Sciences, CVS, AbbVie: 5 Health Care Stocks That Led Retail Message Growth Last Week
Speculation over an impending reverse merger, a Phase 2 trial announcement, comments about upcoming cancer screening tests, a Medicare business deal, and an obesity drug partnership sparked buzz among... 
Via Stocktwits
3 Stocks Breaking Out Right Now
These three stocks are touching new all-time highs. 
Via Talk Markets
Topics Stocks / Equities
Is the SPDR S&P 500 ETF Trust the Smartest Investment You Can Make Today?
Via The Motley Fool
Topics ETFs Stocks
3 Cheap Stocks to Buy With Your Tax Refund Check
Via The Motley Fool
2 Dividend Stocks to Buy for a Lifetime of Passive Income
Via The Motley Fool
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years
 
Via Benzinga
How Is The Market Feeling About AbbVie?
 
Via Benzinga
Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Sarepta Therapeutics (NASDAQ:SRPT) and its peers. 
Via StockStory
Topics Artificial Intelligence
AbbVie Becomes Another Big Pharma To Enter Obesity Treatment Race
AbbVie partners with Gubra in a $2.2 billion deal to develop GUB014295, an amylin analog for obesity. The move marks AbbVie's entry into the competitive weight-loss market. 
Via Benzinga
AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion.
This is the drugmaker's first foray into weight-loss drugs. And it's not focusing on GLP-1. 
Via Investor's Business Daily
These Vanguard ETFs Show Where the Smart Money Is Moving Now
Via The Motley Fool
Topics ETFs
4 Sectors That Thrive When Inflation Runs Hot
Sticky inflation and higher-for-longer interest rates is causing a rotation out of technology stocks, here are four sectors for investors hunting for value 
Via MarketBeat
Topics Economy World Trade
3 Reasons ABBV is Risky and 1 Stock to Buy Instead
AbbVie trades at $205.51 per share and has stayed right on track with the overall market, gaining 5.2% over the last six months. At the same time, the S&P 500 has returned 5.1%. 
Via StockStory
Topics Stocks
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
Via The Motley Fool
2 High-Yield Dividend ETFs to Buy to Generate Passive Income
With yields ranging between 3.6% and 7.3%, these dividend ETFs are great bets for generating passive income. 
Via The Motley Fool
Topics ETFs
Gilead Sciences: 4 Reasons This Stock Has Much More To Rise
Gilead Pharmaceuticals is back to highs not seen in a decade as its HIV treatment franchise surges and awaits its 100% effective HIV prevention drug in summer 
Via MarketBeat
Topics Death
Large Cap Biopharmaceutical Metrics And Performance Q1 2025
Tariffs could have big impact on earnings in 2025. 
Via Talk Markets
Topics Stocks / Equities
2 Magnificent Dividend Growth Stocks to Load Up On Right Now
Via The Motley Fool
4 Stocks and 1 Exchange-Traded Fund (ETF) I Can't Stop Buying
Five great investments for any portfolio. 
Via The Motley Fool
What To Expect From BioMarin Pharmaceutical’s (BMRN) Q4 Earnings
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be reporting results tomorrow afternoon. Here’s what you need to know. 
Via StockStory
Trump's Tax Cut Could Add $4.6 Trillion To Deficit, With $48 Billion Tax Relief For Top 100 Firms: Robert Reich
Robert Reich has termed Donald Trump's taxation policies as an "absolutely shameless giveaway," that could shoot up deficit to $4.6 trillion. 
Via Benzinga
Topics Government
< Previous 1 2 3 4 5 6 7 8 9
...
82 83 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.